Article Details

SpliSense Raises $28.5M to Advance Treatments for Rare CF Mutations

Retrieved on: 2021-05-19 13:30:00

Tags for this article:

Click the tags to see associated articles and topics

SpliSense Raises $28.5M to Advance Treatments for Rare CF Mutations. View article details on hiswai:

Excerpt

ASOs are molecules designed to target the messenger RNA (mRNA), the intermediate molecule derived from DNA that guides protein production.

Article found on: cysticfibrosisnewstoday.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up